Plant-Derived Bioactive Compounds in Chronic Obstructive Pulmonary Disease: Targeting Oxidative Stress and Inflammatory Signaling

Chronic obstructive pulmonary disease (COPD) is characterised by persistent airflow limitation arising from chronic inflammation, oxidative stress, mucus hypersecretion, protease–antiprotease imbalance, airway remodelling, and emphysematous destruction. This review evaluates plant-derived bioactive compounds with reported activity against molecular processes implicated in COPD. Resveratrol, kaempferol, quercetin, fisetin, epigallocatechin gallate, gallic acid, ursolic acid, hesperidin, apigenin, and luteolin are examined with emphasis on Nrf2, NF-κB, MAPKs, PI3K/Akt, SIRT1, TLR4, and NLRP3 signalling. In selected cellular and animal models, these compounds have been reported to reduce oxidative stress, inflammatory mediator release, mucus production, metalloproteinase activity, and tissue injury. However, these experimental findings do not establish therapeutic efficacy in patients with COPD. Some also affect autophagy, corticosteroid sensitivity, and pathways associated with cellular senescence. Overall, the evidence is derived mainly from cultured cells and animal models, with limited clinical data. Poor oral bioavailability, rapid metabolism, uncertain pulmonary exposure, formulation variability, dose standardisation, and potential drug interactions remain major translational limitations. Future studies should define pharmacokinetics, lung tissue exposure, optimal formulations, safety, and interactions with standard COPD therapies, followed by adequately powered clinical trials assessing exacerbations, lung function, symptoms, exercise capacity, quality of life, and treatment-related adverse effects in well-defined COPD populations.

Authors

Institutions

Publication Details

Journal
Current Issues in Molecular Biology
Published
2026-11-12
DOI
https://doi.org/10.3390/cimb48111206
Primary Topic
Chronic Obstructive Pulmonary Disease (COPD) Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Plant-Derived Bioactive Compounds in Chronic Obstructive Pulmonary Disease: Targeting Oxidative Stress and Inflammatory Signaling

Prince Kumar Singh, Monisha Banerjee, Shama Parveen, Saurabh Kumar et al.
Current Issues in Molecular Biology
Chronic Obstructive Pulmonary Disease (COPD) Research
article

Plant-Derived Bioactive Compounds in Chronic Obstructive Pulmonary Disease: Targeting Oxidative Stress and Inflammatory Signaling

Prince Kumar Singh, Monisha Banerjee, Shama Parveen, Saurabh Kumar, Osaid Masood
article en

Abstract

Chronic obstructive pulmonary disease (COPD) is characterised by persistent airflow limitation arising from chronic inflammation, oxidative stress, mucus hypersecretion, protease–antiprotease imbalance, airway remodelling, and emphysematous destruction. This review evaluates plant-derived bioactive compounds with reported activity against molecular processes implicated in COPD. Resveratrol, kaempferol, quercetin, fisetin, epigallocatechin gallate, gallic acid, ursolic acid, hesperidin, apigenin, and luteolin are examined with emphasis on Nrf2, NF-κB, MAPKs, PI3K/Akt, SIRT1, TLR4, and NLRP3 signalling. In selected cellular and animal models, these compounds have been reported to reduce oxidative stress, inflammatory mediator release, mucus production, metalloproteinase activity, and tissue injury. However, these experimental findings do not establish therapeutic efficacy in patients with COPD. Some also affect autophagy, corticosteroid sensitivity, and pathways associated with cellular senescence. Overall, the evidence is derived mainly from cultured cells and animal models, with limited clinical data. Poor oral bioavailability, rapid metabolism, uncertain pulmonary exposure, formulation variability, dose standardisation, and potential drug interactions remain major translational limitations. Future studies should define pharmacokinetics, lung tissue exposure, optimal formulations, safety, and interactions with standard COPD therapies, followed by adequately powered clinical trials assessing exacerbations, lung function, symptoms, exercise capacity, quality of life, and treatment-related adverse effects in well-defined COPD populations.

Current Issues in Molecular BiologyVol. 48(11)
University of Lucknow (IN), Hebrew University of Jerusalem (IL), University of California, Berkeley (US)
Good health and well-being
Chronic Obstructive Pulmonary Disease (COPD) Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon